GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (LSE:HVO) » Definitions » Institutional Ownership

hVIVO (LSE:HVO) Institutional Ownership : 13.66% (As of Jun. 10, 2024)


View and export this data going back to 2012. Start your Free Trial

What is hVIVO Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, hVIVO's institutional ownership is 13.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, hVIVO's Insider Ownership is 7.08%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, hVIVO's Float Percentage Of Total Shares Outstanding is 0.00%.


hVIVO Institutional Ownership Historical Data

The historical data trend for hVIVO's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO Institutional Ownership Chart

hVIVO Historical Data

The historical data trend for hVIVO can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 5.82 7.34 8.58 8.65 9.87 10.47 13.08 13.76 13.66 13.66

hVIVO Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


hVIVO (LSE:HVO) Business Description

Industry
Traded in Other Exchanges
Address
42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO (LSE:HVO) Headlines

No Headlines